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Background: Pituitary adenomas, the third most common intracranial tumor, comprise nearly 16.7% of intracranial
neoplasm and 25%-44% of pituitary adenomas are prolactinomas. Prolactinoma represents a complex heterogeneous
mixture of cells including prolactin (PRL), endothelial cells, fibroblasts, and other stromal cells, making it difficult to
dissect the molecular and cellular mechanisms of prolactin cells in pituitary tumorigenesis through high-throughout-
omics analysis. Our newly developed immuno-laser capture microdissection (LCM) method would permit rapid and
reliable procurement of prolactin cells from this heterogeneous tissue. Thus, prolactin cell specific molecular events
involved in pituitary tumorigenesis and cell signaling can be approached by proteomic analysis.
Results: Proteins from immuno-LCM captured prolactin cells were digested; resulting peptides were separated by two
dimensional-nanoscale liquid chromatography (2D-nanoLC/MS) and characterized by tandem mass spectrometry. All
MS/MS spectrums were analyzed by SEQUEST against the human International Protein Index database and a specific
prolactinoma proteome consisting of 2243 proteins was identified. This collection of identified proteins by far
represents the largest and the most comprehensive database of proteome for prolactinoma. Category analysis of the
proteome revealed a widely unbiased access to various proteins with diverse functional characteristics.
Conclusions: This manuscript described a more comprehensive proteomic profile of prolactinomas compared to
other previous published reports. Thanks to the application of immuno-LCM combined with online two-
dimensional nano-scale liquid chromatography here permitted identification of more proteins and, to our best
knowledge, generated the largest prolactinoma proteome. This enlarged proteome would contribute significantly
to further understanding of prolactinoma tumorigenesis which is crucial to the management of prolactinomas.
Introduction
Prolactinomas are the most common pituitary tumors,
representing 25%-44% of all pituitary adenoma cases [1].
Although most are pathologically benign and grow
slowly, prolactinomas show many symptoms in patients:
amenorrhea, galactorrhea and dysgenesis in female
patients and infertility and erectile dysfunction in male.
Moreover, a number of prolactinomas belie their histol-
ogy by perisellar invasion and postoperative recurrence.
Comprehensive molecular dissection of prolactinoma
pathogenesis is demanded for further understanding of
this kind of tumors. Increasing evidences suggest that
characterization at DNA or RNA level alone would not
be sufficient to elucidate the mechanisms of this disease
as lots of posttranslational modifications exist and pitui-
tary adenoma proteomics would offer an efficient means
for a comprehensive analysis of prolactinoma. Desider-
io’s research on human pituitary adenoma proteome
[2-4], plus newly developed proteomics methodologies
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prolactinomas.
LCM allows the isolation of even single cell and
immunohistochemistry (IHC) staining could help to dis-
tinguish specific cell populations, thus, employment of
immuno-LCM could pick up certain cell populations
with specific immuno-phenotype from complex tissues
according to their antigen expression to ameliorate the
problem of tissue heterogeneity in proteomic research
[5,6].
Two-dimensional gel electrophoresis (2-DE) separates
mixture of proteins by their isoelectric point (pI) and
molecular weight (MW), producing a high-resolution
protein map from which protein spots can be processed
individually [7]. While 2-DE serves as a powerful separa-
tion tool, shotgun proteomics combining LC-MS/MS
have emerged as a technique of choice for large-scale
protein studies due to its superior throughput and sensi-
tivity [8].
In a typical shotgun proteomics experiment, a com-
plex protein sample is digested into peptides followed
by separation by 2D-nanoLC/MS, resulting peptides
were loaded into a mass spectrometer for fragmentation
and sequencing. Sequencing results were used to iden-
tify the parent proteins via database searching. High per-
formance duty cycle instruments can fragment hundreds
of peptides in a single LC-MS/MS experiment. However,
a prolactinoma, even from microdissected sample, con-
tains thousands of tryptic peptides. At a given LC elu-
tion time, multiple coeluting peptides would quickly
overwhelm other MS/MS acquisition speed of duty cycle
instruments. In order to identify proteins from a com-
plex mixture with a dynamic range of at least 10
5 [9], it
is crucial to develop technologies with extremely good
resolving power and extraordinary sensitivity. It is
obvious that these challenging tasks will not be achieved
with a single analytical technique but with a combina-
tion of different separation and detection techniques.
As shotgun proteomics could generate such a large
number of protein identifications via high-throughput
2D separation, we combined a 2D peptide-level separa-
tion performed by coupling strong cation exchange
(SCX) with reverse phase (RP) plus SDS-PAGE protein
prefraction to increase dynamic range and proteome
coverage for bottom-up shotgun proteomics [10,11].
In our recently published study we have reported a
novel method for immuno-LCM in frozen sections of
prolactinomas [12]. Microdissected prolactin cells were
solubilized followed by protein separation on SDS-
PAGE gel. The gel slices were then digested and frac-
tions of the resulting peptides were separated by 2D-
nanoLC/MS and characterized by tandem mass spectro-
metry [13]. All MS/MS spectrums were searched by
SEQUEST against the human International Protein
Index (IPI human, version 3.45 fasta with 71983 entries)
database to provide a profile of prolactinoma proteome.
A proteome consisting of 2243 proteins was thereby
acquired. Compared with previous pituitary adenoma
proteome research [2], our proteome contains more
than twenty times the number of proteins identified by
an initial 2-DE map of extracts from a pituitary ade-
noma. Categories of the proteome include low-abun-
dance proteins, membrane proteins, cyclin dependent
kinases (CDK) and phosphoproteins.
Results
Identification and characterization of prolactinoma
proteome
Since one shortcoming of LCM is the number of pure
cells for proteomic analysis was limited, only 100,000
cells were used in this work. Thus, separation steps
were accordingly limited to reduce the sample loss. Pro-
teins from this small number of cells were fractionated
by SDS-PAGE first and the resolved protein gels were
then cut into five sections according to several distinct
protein bands observed within this gel (Fig. 1). The five
s e c t i o n sc u tf r o mt h eS D S - P A G Eg a v et h eo p t i m a l
results in terms of the detection sensitivity and the
number of proteins identified.
Although some proteins were identified from more
than one gel section, each of the five gel sections pro-
vided a large number of unique protein identifications.
In this process, the peptide fragmentation pattern was
matched to the peptides constructed from the theoreti-
cal human International Protein Index (IPI) database. A
less than 5% false positive rate was estimated through
the reverse database search (reverse the protein
sequences in the human protein database). Such strin-
gent criteria in our experiment would eliminate most
peptides that would falsely increase the number of iden-
tified proteins (data not shown).
The matched peptide sequence analyzed by 2D-
nanoLC/MS was identified based on the fragmentation
pattern (MS/MS) as well as mass accuracy of peptide
molecular weight (within 10 ppm). From the digested
peptides of the five gel slices, 122807 MS/MS spectrums
were acquired and these dataw e r eu s e df o rS E Q U E S T -
based database searches. The results from the five gel
slices were combined as shown in Table 1; 28784 pep-
tides including 115 for 5
+ ions, 1373 for 4
+ ions, 5972
for 3
+ ions and 21328 for 2
+ ions were submitted, and
after removal of redundant proteins, 2249 proteins were
finally identified. To our best knowledge, after eliminat-
ing six keratin proteins from skin or hair [2], the 2243
identified proteins represent the largest database of
human pituitary to date(Additional file 1). Among these
identified 2243 proteins, 1802 proteins were identified
with at least two unique peptides representing
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of these identified proteins (as a percentage) was ana-
lyzed using a bioinformatic analysis tool-The Database
for Annotation, Visualization and Integrated by Discov-
ery [14] (DAVID 2009, Version 6) in Fig. 2.
Discussion
Prolactinoma proteome by immuno-laser capture
microdissection
The global analysis of prolactinoma protein expression
complements genomics analysis and may provide
further insight into post-translational modifications
affecting cellular function. The pituitary adenoma
represents a complex heterogeneous mixture of cells
including prolactin (PRL), endothelial cells, fibroblasts,
and other stromal cells. Since Emmert-Buck MR et al
[15] introduced LCM in 1996, this technique has been
widely used to isolate specific cell types from mixture
tissues for biomedical research especially for proteomic
analysis [16-19]. Although this proteomic technique
has been widely used with regard to different aspects
of neurological diseases [20], there are few data avail-
able about proteomic analysis of human pituitary ade-
noma [2,21-24]. Therefore, in two earlier reviews about
pituitary adenoma research Lloyd RV and Xianquan
Zhan pointed out that LCM is a proposed and per-
spective method for pituitary adenoma proteomic ana-
lysis [16,25]. One research about normal pituitary by
immuno-LCM had proved it a valuable technique for
R N Aa n a l y s i s[ 2 6 ] .O u rg r o u ph a sr e c e n t l y
Figure 1 SDS-PAGE of PRL cells. PRL cells collected from LCM were lyzed with urea (7 M) and thiourea (2 M). Solubilized proteins were
separated via SDS-PAGE and stained with Coomassie blue. The gel was cut into five sections based on molecular mass and each section was
subjected to in-gel digestion with trypsin.
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prolactin cells for proteome analysis by immuno-LCM
[12]. In this study we used SDS-PAGE combined with
2D-nanoLC-MS/MS strategies for proteome study to
identify a total of 2243 unique proteins in prolactin
cells. To our knowledge, this is the most comprehen-
sive proteomic analysis of human pituitary adenoma to
date.
Our previous experiments showed that TritonX-100
concentration for immunostaining was optimal at 0.2%
for 4 min by extracting the lipid proteins from the ade-
noma cell surface [12]. Since hematoxylin [27] and IHC
[28] stained tissues have been successfully employed
with mass spectrometry, in order to test the compatibil-
ity of the pretreatment of 0.2% TritionX-100 solution
with mass spectrometry, protein recovery from prolacti-
noma sections without treatment was directly compared
with that from sections processed with the pretreatment
of TrtionX-100, and no significant differences in protein
recovery were observed between the two protocols (data
not shown). The results demonstrated that the pretrea-
ment of 0.2% TrtionX-100 for 4 min did not affect pro-
teomic analysis. In addition, the novel pretreatment
provided improved morphological discrimination of pro-
lactin cells for successful and easy LCM.
A comparison between two pituitary adenoma proteomes
In an earlier pituitary adenoma proteome research by 2-
DE [2], the authors identified 111 proteins. Most of the
2-DE-separated spots were distributed in the area of pH
4-8 and mass 20-80 kDa. The mean MW of the pro-
teome was 41.8 kDa, and the highest MW protein was
“complement C3 precursor (fragment)” which had a
187.1 kDa MW and the lowest MW protein was “Myo-
sin light chain alkali. Smooth muscle isoform” with a 6.5
kDa MW. The mean pI was 6.13, and the highest pI
protein was “RAB GDP dissociation inhibitor beta”
which had a 9.8 pI and the lowest pI protein was “Myo-
sin light chain alkali” with a 4.38 pI respectively. For the
39 LC-ESI MS/MS characterized proteins, the number
of matched peptides ranged from 2 to 18. The sequence
coverage of these MS/MS data ranged from 7% to 56%.
While for the 96 MALDI characterized proteins, the
number of matched peptides ranged from 4 to 19. The
sequence coverage of these PMF data ranged from 7%-
73%.
Most of the identified proteins (70%) MW in our
research theoretically distributed between 20 kDa and
100 kDa (mean MW = 75.3 kDa). Nevertheless, there
were still some proteins with an extremely low or high
MW in our database. Thirteen proteins with MW <10
Table 1 Number of proteins identified in each gel section
Section number Section 1 Section 2 Section 3 Section 4 Section 5
Number of protein 747 805 769 672 346
Protein matched ≥ 2 peptides 608 662 647 546 265
Figure 2 Categories of identified proteins in prolactinomas by cell components. The distribution of enrolled proteins in DAVID 2009 was
16% of cell part, 15% of intracellular part, 15% of intracellular, 12% of vesicle, 4% of protein complex and other 11 fractions according to cell
components.
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regulated skeletal muscle growth protein 5” (IPI
00063903.5) which has a theoretical MW of 6457 Da
(identified from gel section 5). A total of 143 proteins
with MW of >200 kDa were identified; the largest pro-
tein identified in this work was “isoform of titin” (identi-
fied from protein section 1) which has a theoretical MW
of 3805759 (IPI 00023283.3). The pI range of the pro-
teome was between 3.93 and 12.05 (mean pI = 6.94),
among which 16.7% of proteins were high basic proteins
with pI greater than 9. The lowest and the highest pI
protein were “isoform 1 of acidic leucine-rich nuclear
phosphoprotein 32 family member B” (IPI 00007423.1)
in section 2 (pI = 3.93) and “isoform 1 of serine/arginine
repetive matrix protein 2 (IPI 00782992.3) in section 4
(pI = 12.05). Those proteins either with extreme mole-
cular weights or pIs can be rarely detected by traditional
2-DE analysis of pituitary adenoma. In this new pituitary
adenoma proteome, the number of matched peptides
ranged from 1 to 128. The sequence coverage of these
MS/MS data ranged from 0.1%-87%. (Table 2). The
smallest sequence coverage in our research was quite
lower than that of Zhan’s results. There are many more
high MW proteins identified in our report with only
two or more peptides were matched to these proteins.
However, low sequence coverage these proteins have,
these proteins were identified with a high probability.
Using SDS-LC-MS/MS, Tomazella et al [29] identified
251 total cellular proteins from resting human neutro-
phils, that is more than ten times of proteins identified
by an initial proteome analysis of human neutrophils
and almost five times of proteins identified by the first
2-DE map of extracts of rat polymorphonuclear leuko-
cytes. With SDS-2D-nanoLC-MS/MS in this research,
the total number of identified proteins was substantially
increased to 2243 and there are 79 in common between
the two proteomes (Fig. 3). This might be explained
with: (i) any proteome carried out by the present pro-
teomic technology is only part of the “whole” proteome.
There were differences in any different proteomes even
t h e yw e r ef r o mt h es a m es a m p l ea n dM S ;( i i )t r a n s -
membrane proteins and Less abundant proteins were
not easily extracted or identified in 2-DE studies either
due to their hydrophobicity and aggregation during IEF,
or low abundance [30]; (iii) In fact, many of the spots
detected in the gels were actually variations of the pro-
ducts of post-translationally modified proteins [31] that
were not usually detected by shotgun sequencing and
thus can be a limiting factor of the shotgun approach;
(iv) Pituitary adenomas were divided into six types
according to the hormone secreted (GH,PRL,ACTH,
TSH,LH,FSH) and each type of adenoma has its unique
protein expression characters. Our proteome was from
the pure prolactin cells of prolactinomas by immuno-
LCM while the other proteome by Xianquan Zhan was
from the whole non-functional adenoma tissues [2],
which may be the main reason for the difference.
In our experience, 2-DE identified and revealed rela-
tive distribution of more abundant proteins whereas LC-
ESI-MS/MS identified less abundant proteins and
hydrophobic proteins not amenable to detection by 2-
DE. After the immuno-LCM procedure, cells were lyzed
and fractionated by molecular weight differences using
SDS-PAGE, because SDS-PAGE was not only an effec-
tive pre-fractionation method [32], but also provided
approximate molecular weight information for identified
proteins [33]. One previously described immunostaining
method for proteomics was based on immunogold
detection and involved very short incubation times (5
min) and very high antibody titers (1/25-1/5) [34]. Such
extreme ICH conditions have several potential draw-
backs. In many cases, especially when using polyclonal
antibodies, the background staining could be very high.
In contrast to previously reported studies, we have
demonstrated the membrane-mounted sections pretreat-
ment of the frozen prolatinoma sections with 0.2% Tri-
ton X-100 with a less drastic modifications to
conventional IHC staining protocols was highly compa-
tible with 2D-LC shot gun proteomic studies. The
results obtained from this research clearly proved the
capability of 2D-nano LC-MS/MS tandem mass spectro-
metry for the separation and identification of complex
peptide samples compared with traditional 2-DE meth-
ods. Although some differences existed, both proteomes
complemented each other and contributed to the eluci-
dation of the mechanisms of prolactinoma.
Bioinformatics of the prolactinoma proteome
The protein biological process and functional categories
provided an overview of the human pituitary adenoma
tissue proteome based on the known or postulated
Table 2 Quality comparison of pituitary proteome by 2-DE and 2D-nanoLC/MS Table 2 indicated the quality
comparison between the two pituitary adenoma proteomes on the number of matched peptides, matched peptides
ratios, the percentage sequence coverage, pI range, MW range, mean pI and mean MW.
Methods Number Matched peptides Sequence coverage Mean pI pI range Mean MW (KDa) MW range
MS/MS 39 2-18 7-56% 6.13 4.4-9.4 41.8 12.1-180.7
PMF 96 4-19 7-73%
MS/MS 2249 1-128 0.1-87% 6.95 3.9-12.1 75.3 6.5-380.6
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teome with DAVID revealed a notable identification of
proteins participating in pituitary hormones, cellular sig-
nals, biosynthetic process, cellular metabolic process,
cell development, response to endogenous stimulus,
transportation, etc. Such functional groups are in agree-
ment with pituitary biology in previous research [35-38].
The full classification of the proteins according to their
biological functions is demonstrated in the pie chart in
Fig. 4. Among the identified proteome, 2164 proteins
that are potentially relevant to the biological process of
proteome not yet been described in any of the papers
researching pituitary adenomas cited above. Many pro-
teins play complex biological roles, so in our research
the total number of all subgroups was larger than that
of the whole proteome. Our data suggests that SDS-
PAGE protein prefraction coupled with 2D-nanoLC/MS
peptide separations was still required to maximize the
separation capacity to meet the challenge of the com-
plexity of the prolactinoma proteome.
Several functionally important proteins pertinent to
biological action of the prolactinoma were identified in
this database which had been widely investigated in dif-
ferent aspects of pituitary adenoma.
Cyclin proteins: Cyclins and cyclin dependent kinases
(CDK) (Isoform 1 of CDK Substrate, cyclin G-associated
kinase and isoform 1 of calcyclin-binding protein were
identified in the proteome database) are essential for
cell cycle regulation in eukaryotes. Active cyclin-CDK
complexes drive cells through cell cycle phases by phos-
phorylating the protein substrates that are essential for
the transition to the next phase [39]. Several researches
have found that prolactinomas significantly express
cyclin gene and some cyclin genes may be a marker for
invasion of prolactinomas and may also be related to
tumor recurrence [40].
G-type cyclins (G1 and G2): G-type cyclins seem to
participate in G2-M arrest in response to DNA damage
[41]. G-type cyclins bind to GAK that is a serine/threo-
nine cyclin G-associated kinase involved in epidermal
growth factor receptor signaling [42]. G-type cyclins are
targets of p53 and seem to be involved in the ATM-
p53-Mdm2 pathway [43].
The 14-3-3 family of proteins identified in the list had
a further significance. The 14-3-3 (Ywha or 3-monooxy-
genase/tryptophan 5-monooxygenase activation protein)
family consists of highly conserved, approximately 30
kDa acidic proteins that form homodimers or heterodi-
m e r s[ 4 4 ] .I nm a m m a l s ,u pt os e v e nh o m o l o g o u si s o -
f o r m so ft h i sk i n do fp r o t e i n sh a v eb e e nd e s c r i b e d( bg
δεζh θ) [45] (14-3-3 protein θ/δ, 14-3-3 protein ε, iso-
form long of 14-3-3 protein b/a, 14-3-3 protein h, 14-3-
3p r o t e i ng and 14-3-3 protein θ were detected in this
research). The 14-3-3 family members mediate signal
transduction by binding to phosphoserine-containing
proteins. It interacts with CDC
25 (cell division cyclin
25)
phosphatases, RAF1 and p
27 proteins, suggesting its role
in diverse biochemical activities related to signal trans-
duction, such as cell division and regulation. All iso-
forms of 14-3-3 proteins recognize two high affinity
phosphorylation dependent 14-3-3 binding motifs: R(S/
X) XpSXP (mode 1) and RXXXpSXP (mode 2) where
pS is a phosphoserine. 14-3-3 plays a role in the regula-
tion of various cellular signaling events [46]: (i) change
the ability of target protein to interact with other part-
ners; (ii) modify the cellular localization of target pro-
tein; (iii) bridge two target proteins; (iv) change the
activity of the target protein; and (v) protect their target
protein. A recent research has been shown that 14-3-3
is able to act as a sub-cellular localization modifier for
several phosphorylated proteins [47].
The p
27 protein (IPI 00010860.1) belongs to the large
family of cyclin-dependent kinase inhibitors (CDK1).
The p
27 protein regulates the progression of the cell
cycle from the G1 to the S phase. The levels of p
27 pro-
tein in much malignant neoplasm are lower than those
in normal tissues, suggesting that p
27 may act as a sup-
pressor and has a prognostic significance [48]. P
27 pro-
tein has been identified to cause pituitary adenomas
[49,50]. The very low levels of p
27, both native and Thr-
phosphorylated, were seen in pituitary carcinoma [51].
In addition, recurrent pituitary adenomas show signifi-
cantly lower p
27 expression levels (47%) than non-recur-
rent tumors (67.4%) [52]. In one recent research, the
molecular analysis of human pituitary neoplasm has
Figure 3 Protein overlaps of two proteomes. Total proteins are
indicated for each proteome with two circles; subsets in common
(in blue) are indicated within the diagram. It indicates that most
proteins identified in 2-DE (in brown) are overlapped with what
extracted from the prolactinomas by immuno-LCM (in green).
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27Kip1 dereg-
ulation is significantly implicated in pituitary tumorigen-
esis. In particular, proteins involved in cyclin-dependent
kinase regulation or the pRb pathway are altered in
nearly all human pituitary tumors [53].
Limitations
A pooled sample for proteomic profile analysis would
represent a more comprehensive proteome of prolacti-
nomas, but just because the mixture of many samples,
the concentration of some protein would be too low to
be detected by mass spectrometry and thus the integrity
of the proteome was affected. Our team’s next research
would focus on the label-free comparative proteomic
research, each prolactinoma sample will be analyzed by
shotgun proteomics to produce mass spectral peak
intensities and spectral counts, and the relative intensi-
ties of sequence ion fragment peaks within an MS/MS
spectrum will be compared by statistics to get the differ-
ential proteins, and at the same time, an enlarged prola-
tinoma proteome will be obtained.
Though low density Triton X-100 had been proved to
have no obvious affect on proteomic analysis [54], the
pretreatment of TritonX-100 to improve the intensity of
positive prolactin cells in LCM will definitely resulted in
the loss of some proteins in cell membrane. The paraffin
embodied pituitary adenomas sections need no Triton
X-100 treatment during the IHC for LCM which might
be another potential bank for further pituitary adenoma
proteomic research. Our team had finished the experi-
ment to get prolactin cells by LCM from paraffin embo-
died pituitary adenoma samples and the proteins
number was nearly equal to that from frozen samples
(data not shown).
Conclusions
In the present study, the proteome database of prolacti-
nomas demonstrated that immuno-LCM coupled with
2D-nanoLC/MS mass spectrometry, should enable the
analysis of protein expression profiles in defined group
of prolactin cells, allowing us to extend the present pro-
teome research to a wide range of other cell types of
pituitary adenomas. This enlarged proteome will serve
as a more comprehensive complement of understanding
of previous pituitary adenoma proteome researches and
will also provide a basis for label-free comparative pro-
teomics to find the key cellular events of pituitary
tumorigenesis in our future researches.
Materials and methods
Immuno-laser capture microdissection of prolactinomas
This study was performed under approval of the ethics
committee of Huashan Hospital, Fudan University and
informed consents were received from each patient.
Figure 4 Categories of identified proteins in prolactinomas by biological process. Proteins in the proteome participate in pituitary
hormones, cellular signals, biosynthetic process, cellular metabolic process, cell development, response to endogenous stimulus, transportation,
etc.
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lected during operations and cut approximately 3 mm
in diameter for the subsequent frozen sections. Eight-
micrometer sections on membrane-mounted slide
(Microdissect GmbH, Germany) were collected in the
cryostat (Leica CM 1900, Germany) and immediately
fixed in 100% ethanol for 15 min; the sections were
incubated in 0.2% Triton X-100 with Tris-Buffered Sal-
ine (TBS) for 4 min and then incubated at 1:300 dilution
of primary anti-rabbit polyclonal prolactin antibody
(Dako Cytomation, Copenhagen, Denmark) in the TBS
solution for 30 min in a humid chamber, and then were
washed twice for 3 min each in TBS. Afterwards, all sec-
tions were incubated with biotinylated “Universal” sec-
ondary antibody (Dako Cytomation Copenhagen,
Denmark) for 20 min at room temperature. Finally, all
sections were developed with diaminobenzidine (Dako
Copenhagen, Denmark) for 1 to 2 min and counter-
stained with hematoxylin (Sigma Diagnostics, St. Louis,
MO) and the sections were ready for LCM. A Varitas™
Arcturus LCM, combined with IR/UV system (Arcturus
Molecular Devices, CA, USA), provide a narrow ultra-
violet laser beam to “draw around” and cut out the cells
of interest by photo volatilization (20×). A cap would be
placed on the tissue after the UV laser cut the desired
area. The IR laser would tack the polymer to collect the
desired cells. Laser cut parameters were: spot size = 4
μm, power = 80 mW, pulse duration = 15 ms. Time
between pulses = 400 ms. After a successful immuno-
LCM, thirty 8 μm prolactinoma sections from eleven
prolatinomas provided an approximately 6.0 mm
2 sur-
face area which was equal to 100,000 prolactin cells for
the subsequent shotgun proteomic analysis.
Cell lysis and SDS-PAGE gel protein separation
Lysis buffer, containing urea (7 M) and thiourea (2 M),
was added to a 0.5 ml Eppendorf tube connected to the
LCM cap. Captured cells were solubilized by a series of
20 ms sonication bursts, followed by a 20 s ice cooling,
which was repeated five times. The entire extract (~40
μl) was loaded on a gel (SDS-PAGE, 4%-12% gradient)
to separate proteins by molecular weight (MW) [13].
The MWs of the proteins were estimated by a compari-
son with the migration of standard proteins. This plot
yielded a straight line; the MWs of the unknown pro-
teins were determined by this plot, using the mobility
calculated from the migration of the protein spot. After
staining with Coomassie blue, the gel was cut into five
individual sections with molecular mass ranges. Each
section was further minced into small pieces (approxi-
mately 0.5 mm
2) and subjected to destaining cycles of
gel dehydration with ACN and rehydration with
NH4HCO3 buffer (0.1 M, pH 8.0) in order to remove
the Coomassie stain. This procedure was repeated up to
three times until no visible Coomassie stain remained.
T h ei n - g e lp r o t e i n sw e r es u b s e q u e n t l yd i g e s t e dw i t h
sequence level trypsin reagent (250 μl; 8 ng/μl trypsin in
25 mM NH4HCO3, pH 8.0). The trypsin concentration
was based upon an estimate of approximately 3-6 μg
protein per gel section and adjusted if necessary. The
solution was then replaced by 25 mM NH4HCO3 to
cover the gel pieces (100-200 μl) and incubated over-
night at 37°C. If needed, additional ammonium bicarbo-
nate buffer would be added to completely cover the gel
pieces. After digestion, the supernatant of each tube was
transferred to another Eppendorf tube. To extract resi-
dual peptides, the gel pieces were sonicated for 20 min
at 37°C in a solution of 60% ACN/0.5% TFA. The
extraction was repeated twice. The extracts combined
with the primary supernatant were dried in a vacuum
centrifuge for further separation by 2D-nanoLC/MS.
Automated 2D LC-ESI-MS/MS separation and
identification
All the extracted peptides of protein bands from SDS-
PAGE maps were desalted using a 1.3 ml C18 solid
phase extraction column (Sep-Pak® Cartridge, Waters
Corporation, Milford, USA). The dried peptides then
were resuspended in loading buffer (5 mM Ammonium
formate containing 5%ACN, pH 3.0), separated and ana-
lyzed by 2D strong cation-exchange (SCX)/plus
reversed-phase (RP) nano-scale liquid chromatography/
mass spectrometry. The experiments were performed on
a Nano Aquity UPLC system (Waters Corporation, Mil-
ford, USA) connected to an LTQ-Orbitrap XL mass
spectrometer (Thermo Electron Corporation, Bremen,
Germany) equipped with an online nano-electrospray
ion source (Michrom Bioresources, Auburn, USA).
A 180 μm×2 . 4c mS C Xc o l u m n( W a t e r sC o r p o r a -
tion, Milford, USA) packed with a 5 μm polysulfoethyla
spartamide (PolyLC, Columbia, MD, USA) was used for
the first dimension of separation. To recover hydropho-
bic peptides still retained on the SCX column after a
conventional salt step gradient, an RP step gradient
from 15% to 50% acetonitrile (ACN) was applied to the
SCX column [55].
A9μl plug was injected each time to form the step
gradients. The buffers used to form the gradients were
prepared from a 1 M NH4FA stock solution, pH 3.20.
The buffers used for the conventional salt gradient (5-
500 mM) contained 5% ACN, while the buffers prepared
to form the RP step gradient (10%-50% ACN) all con-
tained 500 mM NH4FA. The organic solvent gradient
was carried out following the salt gradient. The plugs
were loaded onto the SCX column at a 4 μl/min flow
rate for 4 min, with a steps as following:(a): 5 mM and
5%ACN, (b) 100 mM and 5%ACN,(c): 200 mM and5%
ACN, (d): 250 mM and 5%ACN, (e): 300 mM and 5%
ACN, (f): 400 mM and 5%ACN (g): 500 mM and 5%
ACN, (h): 500 mM and 15% ACN, (i): 500 mM and 30%
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nium formate (NH4FA) was used to clean the SCX col-
umn twice. The eluted peptides were captured by a trap
column (Waters Corporation, Milford, USA) while salts
were diverted to waste. The trap column (2 cm × 180
μm) was packed with a 5 μm Symmetry® C18 material
(Waters Corporation, Milford, USA). The RP analytical
column (20 cm × 75 μm) was packed with a 1.7 μm
Bridged Ethyl Hybrid (BEH) C18 material (Waters Cor-
poration, Milford, USA), and was used for the second
dimension separation.
The peptides loaded on the RP analytical column were
eluted with a three-step linear gradient. Starting from
5% B to 45% B in 40 min (A: water with 0.1% formic
acid; B: ACN with 0.1% formic acid), increased to 80% B
in 3 min, and then to 5% B in 2 min. The column was
re-equilibrated at initial conditions for 15 min. The col-
umn flow rate was maintained at 300 nl/min and col-
umn temperature was maintained at 35°C. The 1.1 kV
voltage electrospray versus the inlet of the mass spectro-
meter was used. LTQ-Orbitrap XL mass spectrometer
was operated in the data-dependent mode to switch
automatically between MS and MS/MS acquisition. Full-
scan MS spectras with two microscans (m/z 300-1800)
were acquired in the Orbitrap with a mass resolution of
60,000 at m/z 400, followed by ten sequential LTQ-MS/
MS scans. Dynamic exclusion was used with two
repeated counts, 10s repeated duration, and 60s exclu-
sion duration. For MS/MS, precursor ions were acti-
vated using 35% normalized collision energy at the
default activation q of 0.25.
Peptide Sequence and Data Interpretation
Peptides ion eluted in salt gradient were identified by
accurate molecular weight as a precursor ion and the
product-ion spectrum was compared with the theoreti-
cal human protein index database after collision-induced
dissociation (CID) of the precursor ion. All MS/MS
spectrums were searched by SEQUEST (V28, revision
12, Thermo Electron Corporation) against the human
International Protein Index (IPI) database. To reduce
false positive identification results, a decoy database
containing the reverse sequences was appended to the
database. The searching parameters were set up as fol-
lows: two missed cleavages partial trypsin were consid-
ered, the variable modification was oxidation of
methionine, the peptide mass tolerance was 10 ppm,
and the fragment ion tolerance was 1 Da. Trans Proteo-
mic Pipeline software (revision 4.0 Institute of Systems
Biology, Seattle, WA) was then utilized to identify pro-
teins based upon corresponding peptide sequences with
more than 95% confidence. The peptides results were
filtered by peptide prophet [56] with a P-value over 0.05
then a protein prophet [57] probability of 0.95 was used
for the protein identification.
Additional file 1: Prolactinoma proteome database. Microsoft Excel
spreadsheet (XLS format) containing the proteome database for prolactin
cells isolated from prolactinomas by immuno-LCM.




2D: two-dimensional; IHC: Immunohistochemistry; 2-DE: two-dimensional
electrophoresis; MS: mass spectrometry; SDS-PAGE: Sodium dodecylsulfate
polyacrylamide gel electrophoresis; MALDI-TOF: Matrix-assisted laser
desorption/ionizationtime of flight mass spectrometry; ESI: Electrospray
ionization; TBS: Tris-Buffered Saline; ACN: acetonitrile; SCX: strong cation-
exchange; RP: reversed-phase; LTQ: linear trap quadrupole; LCM: laser
capture microdissection; PRL: prolactin; nanoLC/MS: nano-scale liquid
chromatography/mass spectrometry; PMF: Peptide Mass Fingerprinting; pI:
isoelectric Point; MW: molecular weight
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